Debate: Frontline Regimen For Newly Diagnosed Transplant Ineligible Myeloma - Three Drugs

Debate: Frontline Regimen for Newly Diagnosed Transplant Ineligible Myeloma - Three Drugs

Debate: Frontline Regimen for Newly Diagnosed Transplant Ineligible Myeloma - Two Drugs

Should Frontline Myeloma Treatment Include a 3- or 4-Drug Regimen?

Targeted Oncology

Debate: Optimal Induction Therapy for Newly Diagnosed Transplant Eligible Myeloma - Triplets

Myeloma: Frontline Therapy for Transplant Ineligible Patients

Overall Survival Results in Transplant-Ineligible Newly Diagnosed MM pts: Phase 3 MAIA Study

International Myeloma Foundation

Quadruplets in Newly Diagnosed Transplant-Ineligible Myeloma

Blood Cancer Talks Podcast

First-Line or Frontline Therapy Options In Multiple Myeloma | 2023 IMF Patient and Family Seminar

International Myeloma Foundation

IMROZ- IsaRVd vs RVd in Newly Diagnosed Transplant Ineligible MM | Thierry Facon, MD | EHA 2024

HealthTree Foundation for Multiple Myeloma

Best Treatment Options for Transplant Ineligible Myeloma Patients: Doublets-Triplets?

What is the Best Treatment for Transplant-ineligible Myeloma Patients: 2, 3 or 4 drugs?

Treating Myeloma: Newly Diagnosed Transplant-Eligible Patients

Myeloma: Frontline Therapy for Transplant Eligible Patients

Practical Implications of the MAIA Study for MM

Frontline Therapy in Myeloma for Transplant Ineligible Patients

Dr Mazzoni on the Use of Quadruplet Regimens in Newly Diagnosed Myeloma

Frontline transplant-ineligible MM treatment

VJHemOnc – Video Journal of Hematology & HemOnc

IMROZ: Isa-VRd vs VRd for transplant-ineligible newly diagnosed multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Multiple Myeloma Update: Frontline Therapy

Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed multiple myeloma